Longitudinal quality of life (QoL) study in a randomized phase II trial (FFCD 9803) assessing LV5FU2, LV5FU2-cisplatin or LV5FU2-irinotecan in patients (pts) with metastatic gastric adenocarcinoma (MGA)

F. Bonnetain; O. Bouche; J.-L. Raoul; M. Giovannini; P.-L. Etienne; L. Bedenne; J.-F. Seitz; G. Lledo; T. Conroy; P. Arveux

doi:10.1200/jco.2004.22.90140.4150

Longitudinal quality of life (QoL) study in a randomized phase II trial (FFCD 9803) assessing LV5FU2, LV5FU2-cisplatin or LV5FU2-irinotecan in patients (pts) with metastatic gastric adenocarcinoma (MGA)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.4150 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4150-4150

Author(s):

F. Bonnetain ◽

O. Bouche ◽

J.-L. Raoul ◽

M. Giovannini ◽

P.-L. Etienne ◽

...

Keyword(s):

Quality Of Life ◽

Gastric Adenocarcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Randomized Phase Ii

Download Full-text

Longitudinal quality of life (QoL) study in a randomized phase II trial (FFCD 9803) assessing LV5FU2, LV5FU2-cisplatin or LV5FU2-irinotecan in patients (pts) with metastatic gastric adenocarcinoma (MGA)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.4150 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4150-4150 ◽

Cited By ~ 2

Author(s):

F. Bonnetain ◽

O. Bouche ◽

J.-L. Raoul ◽

M. Giovannini ◽

P.-L. Etienne ◽

...

Keyword(s):

Quality Of Life ◽

Gastric Adenocarcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Randomized Phase Ii

Download Full-text

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

Annals of Oncology ◽

10.1093/annonc/mdi047 ◽

2005 ◽

Vol 16 (2) ◽

pp. 282-288 ◽

Cited By ~ 83

Author(s):

M.M. Borner ◽

J. Bernhard ◽

D. Dietrich ◽

R. Popescu ◽

M. Wernli ◽

...

Keyword(s):

Quality Of Life ◽

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guérin Instillation Therapy on the Quality of Life in Patients with Nonmuscle Invasive Bladder Cancer: Results of a Prospective, Randomized, Phase II Trial

The Journal of Urology ◽

10.1016/j.juro.2013.03.097 ◽

2013 ◽

Vol 190 (3) ◽

pp. 857-862 ◽

Cited By ~ 25

Author(s):

Paolo Gontero ◽

Marco Oderda ◽

Anja Mehnert ◽

Alberto Gurioli ◽

Francesco Marson ◽

...

Keyword(s):

Quality Of Life ◽

Bladder Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Bacillus Calmette Guerin ◽

Instillation Therapy ◽

Randomized Phase Ii ◽

The Impact ◽

Nonmuscle Invasive Bladder Cancer

Download Full-text

Commentary on “The impact of intravesical gemcitabine and 1/3 dose bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: Results of a prospective, randomized, phase II trial.” Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I, Rink M, Schmid M, Kluth LA, Pappagallo G, Sogni F, Sanguedolce F, Schiavina R, Martorana G, Shariat SF, Chun F.

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2014.03.021 ◽

2015 ◽

Vol 33 (1) ◽

pp. 46-47

Author(s):

Ashish Kamat

Keyword(s):

Quality Of Life ◽

Bladder Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Bacillus Calmette Guerin ◽

Instillation Therapy ◽

Randomized Phase Ii ◽

The Impact ◽

Nonmuscle Invasive Bladder Cancer

Download Full-text

Randomized Phase II Trial of Either Fluorouracil, Parenteral Hydroxyurea, Interferon-??t-2a, and Filgrastim or Doxorubicin/Docetaxel in Patients with Advanced Gastric Cancer with Quality-of-Life Assessment

The Cancer Journal ◽

10.1097/00130404-200205000-00013 ◽

2002 ◽

Vol 8 (3) ◽

pp. 282-286 ◽

Cited By ~ 16

Author(s):

Scott Wadler ◽

Carlos Brain ◽

Paul Catalano ◽

Avi I. Einzig ◽

David Cella ◽

...

Keyword(s):

Quality Of Life ◽

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Life Assessment ◽

Quality Of Life Assessment ◽

Randomized Phase Ii

Download Full-text

Late toxicity and quality of life from GETUG-AFU 22 study: A randomized phase II trial comparing 6 months of degarelix in combination with radiotherapy to radiotherapy alone for patients with detectable PSA after radical prostatectomy

European Urology Open Science ◽

10.1016/s2666-1683(20)33522-9 ◽

2020 ◽

Vol 19 ◽

pp. e1398-e1399

Author(s):

P. Sargos ◽

S. Guerif ◽

J. Fraisse ◽

E. Meyer ◽

S. Supiot ◽

...

Keyword(s):

Quality Of Life ◽

Radical Prostatectomy ◽

Phase Ii ◽

Phase Ii Trial ◽

Late Toxicity ◽

Randomized Phase Ii ◽

Radiotherapy Alone

Download Full-text

80 Toxicity and Quality of Life Results from a Randomized Phase II Trial of HDR Monotherapy for Low and Intermediate-Risk Prostate Cancer

Radiotherapy and Oncology ◽

10.1016/s0167-8140(19)33371-7 ◽

2019 ◽

Vol 139 ◽

pp. S36

Author(s):

Yaser Hasan ◽

Andrew Loblaw ◽

Hans Chung ◽

Merrylee McGuffin ◽

Chia-Lin Tseng ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Intermediate Risk ◽

Randomized Phase Ii ◽

Risk Prostate Cancer

Download Full-text

Toxicity and Quality of Life Results from a Randomized Phase II Trial of HDR Monotherapy for Low and Intermediate-Risk Prostate Cancer

Brachytherapy ◽

10.1016/j.brachy.2019.04.113 ◽

2019 ◽

Vol 18 (3) ◽

pp. S53-S54

Author(s):

Yaser Hasan ◽

Andrew Loblaw ◽

Hans Chung ◽

Merrylee McGuffin ◽

Chia-Lin Tseng ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Intermediate Risk ◽

Randomized Phase Ii ◽

Risk Prostate Cancer

Download Full-text

18 / PILOT RANDOMIZED PHASE II TRIAL OF THE ENHANCING QUALITY OF LIFE IN PATIENTS (EQUIP) INTERVENTION FOR PATIENTS WITH ADVANCED LUNG CANCER

10.26226/morressier.5afadd8bf314ac000849b2ee ◽

2018 ◽

Author(s):

Grace Yang

Keyword(s):

Quality Of Life ◽

Lung Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Advanced Lung Cancer ◽

Randomized Phase Ii

Download Full-text

Toxicity and Quality of Life Outcomes from a Randomized Phase II Trial of HDR Monotherapy for Low and Intermediate-Risk Prostate Cancer

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2019.06.120 ◽

2019 ◽

Vol 105 (1) ◽

pp. S133

Author(s):

Y. Hasan ◽

D.A. Loblaw ◽

H.R. Chung ◽

M. McGuffin ◽

C.L. Tseng ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Intermediate Risk ◽

Life Outcomes ◽

Quality Of Life Outcomes ◽

Randomized Phase Ii ◽

Risk Prostate Cancer

Download Full-text